Advancing mRNA-LNP Autoantigen Therapies: Engineering Peripheral Tolerance & Driving Toward First-in-Human Studies
- Explore how mRNA-encoded beta-cell autoantigens with immune modulators drive peripheral tolerance
- Delve into lipid nanoparticle delivery facilitating tolerogenic antigen presentation and Treg-aligned immunoreprogramming
- Discover the translational trajectory toward first-in-human studies in 2027, encompassing CMC scale-up, toxicology studies, and early regulatory engagement to validate safety, manufacturability, and indication expansion